Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Therapy-related acute myeloid leukemia (t-AML) in most cases develops after chemotherapy of other malignancies and shows characteristic chromosome aberrations. Two general types of t-AML have previously been identified. One type is observed after therapy with alkylating agents and characteristically presents as therapy-related myelodysplasia with deletions or loss of the long arms of chromosomes 5 and 7 or loss of the whole chromosomes. The other type is observed after therapy with topoisomerase II inhibitors and characteristically presents as overt t-AML with recurrent balanced chromosome aberrations. Recent research suggests that these 2 general types of t-AML can now be subdivided into at least 8 genetic pathways with a different etiology and different biologic characteristics.

Type

Journal article

Journal

Blood

Publication Date

15/03/2002

Volume

99

Pages

1909 - 1912

Keywords

Acute Disease, Animals, Antineoplastic Agents, Alkylating, Chromosome Aberrations, DNA Methylation, DNA Topoisomerases, Type II, Humans, Leukemia, Myeloid, Mice, Models, Genetic, Myelodysplastic Syndromes, Neoplasms, Second Primary, Promoter Regions, Genetic